All Stories

  1. Position Statement of the EADV Task Forces With External Experts on Quality of Life Measurement in Hidradenitis Suppurativa: An Update
  2. The enigma of hidradenitis suppurativa: Michelangelo's "Awakening Slave"
  3. Patient-reported triggers of primary hyperhidrosis
  4. Health-related Quality of Life Measurements in Patients with Actinic Keratosis: A Systematic Review
  5. Suicide in patients with skin diseases: What to look out for?
  6. Why do you want to see a dermatologist?
  7. Dermatophyte contamination of hair clippers and cleaning brushes in Copenhagen hair salons
  8. Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial
  9. Management of Severe Bilateral Axillary Hidradenitis Suppurativa in a Resource‐Limited Setting: A Case Report and Review of the Literature
  10. Grand Challenges for Skin Health Revisited: The International League of Dermatological Societies (ILDS) Skin Disease Atlases
  11. It is still a secret disease – clinical images in randomized controlled trials on hidradenitis suppurativa
  12. Rental shoes are not a source of tinea pedis
  13. Preparing for Polygenic Risk Scores in the clinic: an accessible guide to reading and interpreting GWAS
  14. Diagnostic Accuracy of a Questionnaire Screening Test in Assessing the Prevalence of Hidradenitis Suppurativa in Sydney, Australia
  15. Global Hidradenitis Suppurativa Epidemiology: Exploring Themes and Gaps beyond Europe, Australia, and the USA
  16. Hidradenitis Suppurativa Prevalence in Indonesia: A Cross-Sectional Multicenter Study and Validation of a Screening Questionnaire
  17. Hidradenitis Suppurativa Prevalence in Santiago, Chile
  18. Prevalence of Hidradenitis Suppurativa among Healthy Adults in Abuja, Nigeria
  19. Prevalence of Hidradenitis Suppurativa in Antalya, Türkiye
  20. Prevalence of Hidradenitis Suppurativa in Athens, Greece: A Cross-Sectional Study Based on a Validated Questionnaire
  21. Prevalence of Hidradenitis Suppurativa in Balangoda, Sri Lanka
  22. Prevalence of Hidradenitis Suppurativa in Brussels, Belgium: Validation of a Screening Questionnaire
  23. Prevalence of Hidradenitis Suppurativa in Bucharest, Romania
  24. Prevalence of Hidradenitis Suppurativa in Darmstadt, Germany: A Contribution to the Global Hidradenitis Suppurativa Atlas
  25. Prevalence of Hidradenitis Suppurativa in Dhaka, Bangladesh: A Hospital-Based Study
  26. Prevalence of Hidradenitis Suppurativa in Durban, KwaZulu-Natal South Africa
  27. Prevalence of Hidradenitis Suppurativa in Fars Province, Iran
  28. Prevalence of Hidradenitis Suppurativa in Hospital Kuala Lumpur, Malaysia: A Cross-Sectional Study
  29. Prevalence of Hidradenitis Suppurativa in Lund and Gothenburg, Sweden: An Analysis from the Global Hidradenitis Suppurativa Atlas Initiative
  30. Prevalence of Hidradenitis Suppurativa in Oman
  31. Prevalence of Hidradenitis Suppurativa in Poland
  32. Prevalence of Hidradenitis Suppurativa in Saudi Arabia
  33. Prevalence of Hidradenitis Suppurativa in Serbia: Validation of a Screening Questionnaire
  34. Prevalence of Hidradenitis Suppurativa in Skopje, North Macedonia
  35. Prevalence of Hidradenitis Suppurativa in the Gulf Province of Papua New Guinea
  36. Prevalence of Hidradenitis Suppurativa in the Netherlands: A Cross-Sectional Study as Part of the Global Hidradenitis Suppurativa Atlas (GHiSA)
  37. Prevalence of Hidradenitis Suppurativa in Lyon: Results from the French Team of the Global Hidradenitis Suppurativa Atlas Project
  38. Methylene blue photodynamic therapy of antifungal-unresponsive (resistant) dermatophytosis
  39. Predictors of perceived stress, perceived stigmatization, and body dysmorphia in patients with chronic prurigo/prurigo nodularis: Results from an observational cross-sectional multicenter European study in 17 countries
  40. A genome-wide association meta-analysis links hidradenitis suppurativa to common and rare sequence variants causing disruption of the Notch and Wnt/β-catenin signaling pathways
  41. Introducing Social Dermatology
  42. Botulinum toxin type A efficacy on pain and suppuration in hidradenitis suppurativa
  43. Rhinophyma treatment: An observational study comparing the results of the cold blade technique and ablative fractional CO2-laser
  44. Quality‐of‐Life Measurement in Epidermolysis Bullosa. Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient‐Oriented Outcomes and External Experts
  45. Validation of new items for diagnosing primary hyperhidrosis, and estimation of the prevalence of primary hyperhidrosis
  46. Evaluation of Health Education Based on Pictograms and Video Sequences in the Prevention of Hand Eczema Among Hospital Cleaners: A Cluster‐Randomised Controlled Trial With 24 Weeks Follow‐Up
  47. Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be)
  48. Genetic Susceptibility to Hidradenitis Suppurativa and Predisposition to Cardiometabolic Disease
  49. Questionnaire-Based Global Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis
  50. Prevalence of Hidradenitis Suppurativa in Xi’an, China: A Single Center Epidemiological Study
  51. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
  52. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial
  53. The Prevalence of Hidradenitis Suppurativa in Calgary, Alberta, Canada: Results from a Participating Site in the Global Hidradenitis Suppurativa Atlas Cross-Sectional Study
  54. DNA methylation patterns of circadian and ultradian genes are altered in the peripheral blood of patients with hidradenitis suppurativa
  55. Stigmatization and perceived health status in patients with hidradenitis suppurativa: an observational multicenter study in Europe
  56. Factors Associated with Severe Hidradenitis Suppurativa, Using Hurley Staging and Metascore
  57. Identification of Novel Genetic Risk Variants Associated with Hidradenitis Suppurativa in an Exome Sequencing Cohort of 92,455 Individuals
  58. A systematic review and meta-analysis of psychiatric diseases in individuals with primary hyperhidrosis
  59. Alpha‐1 antitrypsin deficiency associated with increased risks of skin cancer, leukemia, and hepatic cancer: A nationwide cohort study
  60. Hidradenitis suppurativa and female infertility: a pilot study conducted amongst 110 dermatological patients
  61. Microenvironmental host–microbe interactions in chronic inflammatory skin diseases
  62. Common efficacy measures and measurement instruments lead to more meaningful clinical research
  63. Pharmacies Counselling of Patients in the Era of Antifungal Resistance
  64. Prevalence of hidradenitis suppurativa in a Turkish population: validation of a screening questionnaire in Istanbul, Turkey
  65. Cluster Analysis Identifies Clinical Phenotypes of Primary Hyperhidrosis
  66. The Nationwide Epidemiology of Patients Treated for Hidradenitis Suppurativa by a Dermatologist in the Faroe Islands
  67. Sex-related Variations in Comorbidities in Lichen Sclerosus: A Systematic Review and Meta-Analysis
  68. A cross‐sectional study on gender differences in body dysmorphic concerns in patients with skin conditions in relation to sociodemographic, clinical and psychological variables
  69. Reporting of self‐reported hand eczema as an occupational disease in hospital cleaners: A cross‐sectional questionnaire‐based study
  70. Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement
  71. Exploring treatment and antifungal resistance in an outbreak of tinea caused by Microsporum audouinii
  72. Quality of life measurement in urticaria: Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient‐Oriented Outcomes and Urticaria and Angioedema
  73. The correlation between self‐reported hand eczema and clinically based diagnosis in professional cleaners
  74. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
  75. Hidradenitis Suppurativa Prevalence in Algeria: A Multicenter Cross-Sectional Study
  76. Rosacea Core Domain Set for Clinical Trials and Practice
  77. Deregulated Long Non-Coding RNAs (lncRNA) as Promising Biomarkers in Hidradenitis Suppurativa
  78. Assessment of metabolic dysfunction‐associated steatotic liver disease in patients with hidradenitis suppurativa: A cross‐sectional study
  79. An Explorative Study on Calcium Electroporation for Low-risk Basal Cell Carcinoma
  80. Increased risk of nonmelanoma skin cancer in patients with alpha‐1 antitrypsin deficiency: A nationwide cohort study
  81. Increased cancer incidence among patients with hidradenitis suppurativa – a Danish nationwide register study 1977–2017
  82. Professional Cleaners’ and Healthcare Workers’ Ability to Recognize Hand Eczema
  83. Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: Results from a European multi‐centre study
  84. Did We Forget about Social Determinants of Health in Dermatology?
  85. Morphology: the mother of all biomarkers
  86. Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa (HS): results from a Cox proportional hazard regression analysis on disease progression among a cohort of 335 Danish patients with HS
  87. Diagnostic accuracy of a short-form version of the diagnostic criteria for primary hyperhidrosis
  88. Behandlung der Acne fulminans mit Tumornekrosefaktor‐α‐Inhibitoren – eine Übersicht klinischer Fälle und der Literatur
  89. Evaluation of Quality of Life in First‐Degree Relatives of Patients With Hidradenitis Suppurativa Using Family Dermatology Life Quality Index
  90. The Global Hidradenitis Suppurativa Atlas Methodology: Combining Global Proportions in a Pooled Analysis
  91. Orismilast for the treatment of mild to severe hidradenitis suppurativa: Week 16 data from OSIRIS, a Phase 2a, open‐label, single‐centre, single‐arm, dose‐finding clinical trial
  92. Tumor necrosis factor‐α inhibitor treatment of acne fulminans – a clinical and literature review
  93. Viewpoint on the Evaluation of Severity and Treatment Effects in Mild Hidradenitis Suppurativa: The Cumulative IHS4
  94. Psychometric validation of the Ostomy Skin Tool 2.0
  95. Severity rating of specific skin lesions in hidradenitis suppurativa: the patient perspective
  96. Hidradenitis suppurativa associated telomere‐methylome dysregulations in blood
  97. Global consensus process to establish a core data set for hidradenitis suppurativa registries
  98. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice
  99. Global differences in tobacco use: who is using what?
  100. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
  101. Laser and intense pulsed light in the treatment of hidradenitis suppurativa
  102. Knowledge, attitudes, and perceptions of hidradenitis suppurativa among young adults in Singapore
  103. Predictive metagenomic analysis identifies specific bacterial metabolic pathways in hidradenitis suppurativa tunnels
  104. Dynamic Optical Coherence Tomography of Blood Vessels in Cutaneous Melanoma—Correlation with Histology, Immunohistochemistry and Dermoscopy
  105. Skin and Gut Microbiome in Hidradenitis Suppurativa: A Systematic Review
  106. Design and validation of pictograms and educational video clips to improve the knowledge of skin care and protection: Comprehension and recall among professional hospital cleaners
  107. Keratitis-ichthyosis-deafness syndrome and hidradenitis suppurativa
  108. Quality of life in individuals with primary hyperhidrosis: a systematic review and meta-analysis
  109. Hidradenitis suppurativa presents a methylome dysregulation capable to explain the pro‐inflammatory microenvironment: Are theseDNAmethylations potential therapeutic targets?
  110. Prevalence and risk factors for hand eczema among professional hospital cleaners in Denmark: A cross‐sectional questionnaire‐based study
  111. Perceived Stigmatization among Dermatological Outpatients Compared with Controls: An Observational Multicentre Study in 17 European Countries
  112. Attempted treatment of primary axillary hyperhidrosis with one session of either Neodymium YAG laser or Intense Pulsed Light: A within patient randomized trial of treated versus untreated contralateral axilla
  113. The differentiating effect of COVID-19-associated stress on the morbidity of blood donors with symptoms of hidradenitis suppurativa, hyperhidrosis, or psoriasis
  114. Validation of the Hidradenitis Suppurativa Investigator Global Assessment
  115. Confocal microscopy and optical coherence tomography of inflammatory skin diseases in hairs and pilosebaceous units: A systematic review
  116. Nationwide epidemiology and treatment pattern of superficial fungal infections in the Faroe Islands: a retrospective study from 2003 to 2019
  117. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data
  118. Cytochrome P450 Genes Mediated by DNA Methylation Are Involved in the Resistance to Hidradenitis Suppurativa
  119. Primary skin abscess microbiota a systematic review
  120. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project
  121. Optical coherence tomography for presurgical delineation of basal cell carcinomas on the face—A comparison with histopathology
  122. Symptoms of attention deficit hyperactivity disorder are associated with Hidradenitis suppurativa in Danish blood donors
  123. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
  124. Patients with tinea pedis and onychomycosis are more likely to use disinfectants when washing textiles than controls
  125. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
  126. What do professional cleaners know about the skin care? A questionnaire‐based study
  127. Wound drainage measurements: a narrative review
  128. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis
  129. Hidradenitis Suppurativa Prevalence in Nuuk, Greenland: Physician Validation of a Hidradenitis Suppurativa Questionnaire in a Greenlandic Setting
  130. Short‐term real‐world experience with baricitinib treatment in Danish adults with moderate–severe atopic dermatitis
  131. Hyperhidrosis is associated with sleep disturbances, daytime tiredness, stress, and depression: A retrospective cohort study from the Danish Blood Donor Study
  132. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort
  133. Prevalence of Hidradenitis Suppurativa in an African Population: Validation of a Screening Questionnaire in Lagos, Nigeria
  134. The Role of Intra-Follicular Shear Forces in Hidradenitis Suppurativa
  135. Two Novel Human Leukocyte Antigen Alleles Are Associated with Decreased Risk of Onychomycosis in a Large Cohort of Danish Blood Donors
  136. An Increase in Specialist Treatment for Onychomycosis: An Unexplained Tendency. A Retrospective Study of Patients Treated for Onychomycosis in Danish Hospitals from 1994 to 2018
  137. Inflammation of Actinic Keratoses Induced by Combination of Carboplatin and Paclitaxel: Two Case Reports
  138. Validity and reliability of the Rosacea Area and Severity Index: A novel scoring system for clinical assessment of rosacea severity
  139. Prevalence, risk factors, and prevention of occupational contact dermatitis among professional cleaners: a systematic review
  140. Human leukocyte antigen system associations in Malassezia-related skin diseases
  141. Scoring hidradenitis suppurativa: How to simplify data collection?
  142. Development and validation of IHS4‐55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa
  143. Methylated miRNAsmay serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa
  144. Inflamed actinic keratoses as a biomarker in repositioning of chemotherapeutics: a systematic review and meta-analysis
  145. Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study
  146. Prevalence of Hidradenitis Suppurativa in Berekum, Ghana
  147. Systematic review of the prevalence of onychomycosis in children
  148. Registries, multicentre and genome‐wide association studies in hidradenitis suppurativa
  149. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
  150. Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry
  151. The Social and Psychological Impact of Acne Treatment: A Cross-Sectional Study of Blood Donors
  152. Shifting focus from “what we do” to the “impact of what we do”: Application of outcome measures to routine clinical care in dermatology
  153. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
  154. The temporal association of hyperhidrosis and its comorbidities – a nationwide hospital‐based cohort study
  155. Treatment of Hyperhidrosis: An Update
  156. Disinfection trials with terbinafine‐susceptible and terbinafine‐resistant dermatophytes
  157. Communicating with patients through pictograms and pictures – a scoping review
  158. Development and initial validation of the HS‐IGA : a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials*
  159. Body dysmorphia in common skin diseases: results of an observational, cross‐sectional multicentre study among dermatological outpatients in 17 European countries*
  160. Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls
  161. Hyperhidrosis and human leucocyte antigens in the Danish Blood Donor Study
  162. The health-related quality of life in hyperhidrosis and co-morbidities
  163. Prevalence and perceptions towards hidradenitis suppurativa: a cross‐sectional study in a non‐dermatological outpatient population
  164. Prevalence of Marfan syndrome, Ehlers-Danlos syndrome, and osteogenesis imperfecta in patients with hidradenitis suppurativa
  165. Evidence of gene–gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins
  166. Incidence and remission rates of self‐reported hidradenitis suppurativa ‐ A prospective cohort study conducted in Danish blood donors
  167. Quality of Life in Danish Blood Donors Treated for Superficial Fungal Infections
  168. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
  169. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
  170. International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting
  171. Darier’s Disease Flare following COVID-19 Vaccine
  172. Probiotics in hidradenitis suppurativa: a potential treatment option?
  173. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study
  174. Tinea capitis asymptomatic carriers: what is the evidence behind treatment?
  175. Electrochemotherapy with bleomycin for basal cell carcinomas: a systematic review
  176. Hyperhidrosis and the risk of being treated for skin infections
  177. The use of prescriptions for antibiotics and antifungals in Danish blood donors with dry skin
  178. Associations between maternal and environmental exposures on atopic disease in the offspring of mothers with asthma
  179. Optical coherence tomography quantifying photo aging: skin microvasculature depth, epidermal thickness and UV exposure
  180. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
  181. The association between water hardness and xerosis—Results from the Danish Blood Donor Study
  182. Target molecules for future hidradenitis suppurativa treatment
  183. Anti‐COVID‐19 measurements for hidradenitis suppurativa patients
  184. Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary
  185. How to diagnose and measure primary hyperhidrosis: a systematic review of the literature
  186. Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life
  187. Full exome sequencing of 11 families with Hidradenitis suppurativa
  188. Photodynamic therapy: A treatment option for terbinafine resistant Trichophyton species
  189. Intralesional Triamcinolone for Hidradenitis Suppurativa—How Much Is Needed?
  190. Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study
  191. Dynamic optical coherence tomography shows characteristic alterations of blood vessels in malignant melanoma
  192. Hidradenitis Suppurativa Quality of Life (HiSQOL): creation and validation of the Polish language version
  193. Establishment of a Nationwide Patient Database for Clinical Trial Recruitment in Dermatology: Concept and Patient Characteristics
  194. Epidemiology of Hyperhidrosis in Danish Blood Donors
  195. Geosocial Dating Applications Mirror the Increase in Sexually Transmitted Diseases
  196. Risk of Hidradenitis Suppurativa Comorbidities Over Time: A Prospective Cohort Study of Danish Blood Donors
  197. No association between atopic dermatitis and acne vulgaris in the general population
  198. Intense pulsed light treatment for hidradenitis suppurativa: a within-person randomized controlled trial
  199. Superficial fungal infections and patients with hidradenitis suppurativa: a study under the Danish Blood Donor Study
  200. Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series
  201. Mechanical forces and Hidradenitis Suppurativa
  202. Metascoring Hidradenitis suppurativa
  203. Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study
  204. European registry for hidradenitis suppurativa: state of play
  205. A survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa
  206. Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia
  207. Sub-classification of Hidradenitis suppurativa: a cross-sectional study
  208. An increase in use of antifungals for superficial infections in Denmark during 1997–2018
  209. What causes hidradenitis suppurativa ? – 15 years after
  210. Occupational Skin Disease in Physicians: A Review of the Literature
  211. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa*
  212. Photodynamic therapy treatment of superficial fungal infections: A systematic review
  213. What counts? The relationship between patient estimated numbers of painful hidradenitis suppurativa lesions over 4 weeks compared with clinician's lesion count at the time of examination
  214. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life
  215. Emergency Doctor's ability to diagnose Hidradenitis Suppurativa
  216. Further evidence for the immediate knowledge improvement through EADV Schools on hidradenitis suppurativa/acne inversa
  217. Disease Trajectories for Hidradenitis Suppurativa in the Danish Population
  218. Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round‐table session
  219. Treatment adherence and psychosocial impact of tinea capitis in families: Qualitative pilot study
  220. Dynamic Optical Coherence Tomography Imaging of Telangiectasia Prior to Intense Pulsed Light Treatment—An Opportunity to Target Treatment?
  221. Multimodal management of hidradenitis suppurativa
  222. Body Dysmorphic Disorder in Dermatology: a Systematic Review
  223. Long‐term evaluation of climatotherapy for psoriasis
  224. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year
  225. Cross‐sectional study identifies lower risk of Staphylococcus aureus nasal colonization in Danish blood donors with hidradenitis suppurativa symptoms
  226. Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients
  227. Hidradenitis suppurativa
  228. Systematic Review of Complications and Recurrences After Surgical Interventions in Hidradenitis Suppurativa
  229. Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project
  230. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa
  231. Exploring the EQ-5D Dimension of Pain/Discomfort in Dermatology Outpatients from a Multicentre Study in 13 European Countries
  232. Psychosocial Aspects of Adult Acne: Data from 13 European Countries
  233. Can we clinically identify patients at risk of malignant transformation of skin tumors in Brooke–Spiegler syndrome?
  234. Hidradenitis Suppurativa is Associated with Non-alcoholic Fatty Liver Disease: A Cross-sectional Study
  235. Body Image Quality of Life in Patients with Hidradenitis Suppurativa Compared with Other Dermatological Disorders
  236. Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa
  237. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice
  238. Proposed Definitions of Typical Lesions in Hidradenitis Suppurativa
  239. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials
  240. Predictive Metagenomic Analysis Reveals a Role of Cutaneous Dysbiosis in the Development of Hidradenitis Suppurativa
  241. Invasive dermatophytosis mimicking vasculitis
  242. ‘The psychosocial burden of alopecia areata and androgenetica’: a cross‐sectional multicentre study among dermatological out‐patients in 13 European countries
  243. Optical coherence tomography of onychomycosis: proposed terminology and a suggestion of practical usage
  244. Psoriasis as a comorbidity of hidradenitis suppurativa
  245. Hidradenitis Suppurativa Area and Severity Index ( HASI ): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa
  246. Hidradenitis suppurativa in a cohort of overweight and obese children and adolescents
  247. Itch and Mental Health in Dermatological Patients across Europe: A Cross-Sectional Study in 13 Countries
  248. Genetic disposition to primary hyperhidrosis: a review of literature
  249. Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials
  250. Cutaneous candidiasis – an evidence‐based review of topical and systemic treatments to inform clinical practice
  251. Inter‐rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa
  252. Effective treatment with photodynamic therapy of cutaneous leishmaniasis: A case report
  253. Pain perception in patients with hidradenitis suppurativa
  254. The boiling brain
  255. Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa
  256. EWMA Document: Atypical wounds. Best clinical practice and challenges
  257. DBDS Genomic Cohort, a prospective and comprehensive resource for integrative and temporal analysis of genetic, environmental and lifestyle factors affecting health of blood donors
  258. Pharmacological development in hidradenitis suppurativa
  259. Learning efficacy of the European Academy of Dermatology and Venereology School on hidradenitis suppurativa/acne inversa
  260. Eruptive Melanocytic Nevi: A Review
  261. Family recurrence risk of alopecia areata in the Faroe Islands
  262. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross‐sectional study among 2465 patients
  263. The microbiome of tunnels in hidradenitis suppurativa patients
  264. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient‐Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa
  265. Evidence‐based hidradenitis suppurativa guidelines – and now all together please
  266. KITTEN following CAT on the long‐term use of rifampicin in hidradenitis suppurativa and effectiveness of oral contraceptives
  267. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer
  268. Hidradenitis Suppurativa is a Diagnosis to be Discussed
  269. The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa
  270. Virulent Staphylococcus lugdunensis with limited genetic diversity in hidradenitis suppurativa lesions
  271. Mast cells in hidradenitis suppurativa: a clinicopathological study
  272. Chlorhexidine Allergy: On the Rise and Often Overlooked
  273. Thyroid function in psoriasis
  274. Pediatric toxic epidermal necrolysis treated successfully with infliximab
  275. Alopecia Areata After Treatment with Dupilumab
  276. Bacterial biofilm is associated with higher levels of regulatory T cells in unaffected hidradenitis suppurativa skin
  277. Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument
  278. Long-Wave Medical Infrared Thermography: A Clinical Biomarker of Inflammation in Hidradenitis Suppurativa/Acne Inversa
  279. Occurrence, Chronicity and Intensity of Itch in a Clinical Consecutive Sample of Patients with Skin Diseases: A Multi-centre Study in 13 European Countries
  280. Teledermatology management of difficult-to-treat dermatoses in the Faroe Islands
  281. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
  282. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic
  283. Validation of three‐dimensional wound measurements using a novel 3D‐WAM camera
  284. Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
  285. Nonattendance in an Outpatient Clinic among Patients with Hidradenitis Suppurativa
  286. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group
  287. The vascular morphology of melanoma is related to Breslow index: An in vivo study with dynamic optical coherence tomography
  288. Hidradenitis suppurativa in Korea
  289. Ankle-brachial index in psoriasis: a population-based study
  290. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study
  291. Creation and pilot test results of the dermatology-specific proxy instrument: the Infants and Toddlers Dermatology Quality of Life
  292. Arterial stiffness in subjects with psoriasis: a cross-sectional population study
  293. Dairy Intake and Acne Vulgaris: A Systematic Review and Meta-Analysis of 78,529 Children, Adolescents, and Young Adults
  294. Lactase Persistence, Milk Intake, and Adult Acne: A Mendelian Randomization Study of 20,416 Danish Adults
  295. Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions
  296. Vascular morphology in normal skin studied with dynamic optical coherence tomography
  297. New pathways to explore in hidradenitis suppurativa
  298. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study
  299. The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries
  300. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process
  301. Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes
  302. Hidradenitis suppurativa and intimacy
  303. Thyroid function in hidradenitis suppurativa: a population-based cross-sectional study from Denmark
  304. Pulmonary function in patients with psoriasis: across-sectional population study
  305. Dermatologists across Europe underestimate depression and anxiety: results from 3635 dermatological consultations
  306. Dynamic optical coherence tomography of histamine induced wheals
  307. Blood parameters in a population of blood donors are not affected by hidradenitis suppurativa
  308. Advances in optical coherence tomography in dermatology—a review
  309. Diagnosis and Treatment of Hidradenitis Suppurativa—Reply
  310. Frequency of Electrocardiographic Abnormalities in Patients With Psoriasis
  311. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report
  312. A long‐term follow‐up study of the Hand Eczema Trial (HET): a randomized clinical trial of a secondary preventive programme introduced to Danish healthcare workers
  313. The psychosocial burden of hand eczema: Data from a European dermatological multicentre study
  314. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II
  315. In vivo differentiation of common basal cell carcinoma subtypes by microvascular and structural imaging using dynamic optical coherence tomography
  316. The Role of Therapy in Impairing Quality of Life in Dermatological Patients: A Multinational Study
  317. Swiss (German) Version of the Actinic Keratosis Quality of Life questionnaire
  318. Arguments for a national questionnaire-based screening for hidradenitis suppurativa in Denmark
  319. Increased Suicide Risk in Patients with Hidradenitis Suppurativa
  320. Hidradenitis suppurativa and electrocardiographic changes: a cross-sectional population study
  321. Quimp (quality of life impairment): an addition to the quality of life lexicon
  322. Investigational drugs in clinical trials for Hidradenitis Suppurativa
  323. Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa
  324. Pain during topical photodynamic therapy - comparing methyl aminolevulinate (Metvix®) to aminolaevulinic acid (Ameluz®); an intra-individual clinical study
  325. Topical 15% resorcinol for hidradenitis suppurativa: An uncontrolled prospective trial with clinical and ultrasonographic follow-up
  326. Hidradenitis Suppurativa
  327. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity
  328. Intense pulsed light treatment for patients with hidradenitis suppurativa: beware treatment with resorcinol
  329. Factors predicting the self-evaluated health of hidradenitis suppurativa patients recruited from an outpatient clinic
  330. Body mass index ( Obesity) in hidradenitis suppurativa .
  331. Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa
  332. Self-reported minor infections in patients with hidradenitis suppurativa and healthy controls
  333. Hidradenitis Suppurativa is Associated with Myocardial Infarction, but Not Stroke or Peripheral Arterial Disease of Lower Extremities
  334. Moderate to severe hidradenitis suppurativa patients do not have an altered bacterial composition in peripheral blood compared to healthy controls
  335. Recognizing syndromic hidradenitis suppurativa: a review of the literature
  336. The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls
  337. Dynamic optical coherence tomography of skin blood vessels - proposed terminology and practical guidelines
  338. Use of moisturizers among Danish atopic dermatitis patients-which perceived product characteristics associate with long-term adherence?
  339. In vivo measurements of blood vessels’ distribution in non-melanoma skin cancer by dynamic optical coherence tomography - a new quantitative measure?
  340. Commentary on Ultrasound Evaluation as a Complementary Test in Hidradenitis Suppurativa
  341. A pilot study of fatigue in patients with Hidradenitis suppurativa
  342. Photographic Documentation and Hand Eczema Severity Index for Severity Assessment of Hand Eczema
  343. Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients
  344. In vivo microvascular imaging of cutaneous actinic keratosis, Bowen's disease and squamous cell carcinoma using dynamic optical coherence tomography
  345. Optical coherence tomography in the diagnosis of actinic keratosis—A systematic review
  346. Quality of life considerations and pain management in hidradenitis suppurativa
  347. Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease
  348. Haematoxylin and eosin staining identifies medium to large bacterial aggregates with a reliable specificity: A comparative analysis of follicular bacterial aggregates in axillary biopsies using peptide nucleic acid-fluorescence in situ hybridization and h
  349. Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa
  350. Assessment of subclinical atherosclerosis in hidradenitis suppurativa: Reply to Dr Vinkel's letter
  351. Framingham risk assessment in hidradenitis suppurativa
  352. Imaging Blood Vessel Morphology in Skin: Dynamic Optical Coherence Tomography as a Novel Potential Diagnostic Tool in Dermatology
  353. Treatments for hidradenitis suppurativa
  354. Spanish version of the Actinic Keratosis Quality of Life questionnaire
  355. Bacterial biofilm in chronic lesions of hidradenitis suppurativa
  356. Assessment of subclinical atherosclerosis in hidradenitis suppurativa
  357. Prodromal symptoms in hidradenitis suppurativa
  358. A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark
  359. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes
  360. Normal Skin Microbiota is Altered in Pre-clinical Hidradenitis Suppurativa
  361. Dermatobia hominis misdiagnosed as abscesses in a traveler returning from Brazil to Denmark
  362. Determinants of Psychosocial Health in Psoriatic Patients: A Multi­national Study
  363. Attachment Styles of Dermatological Patients in Europe: A Multi­centre Study in 13 Countries
  364. Impairment of Sexual Life in 3,485 Dermatological Outpatients From a Multicentre Study in 13 European Countries
  365. Editorial
  366. Serum Anticytokine Autoantibody Levels Are Not Increased in Hidradenitis Suppurativa: A Case-Control Pilot Study
  367. High-Frequency Ultrasound of the Nail
  368. Optical Coherence Tomography Imaging of the Skin
  369. Self-Inflicted Lesions in Dermatology: A Management and Therapeutic Approach – A Position Paper From the European Society for Derma­tology and Psychiatry
  370. Hidradenitis Suppurativa
  371. Pathophysiology of Hidradenitis Suppurativa
  372. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series
  373. Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma
  374. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology
  375. Why quality of life measurement is important in dermatology clinical practice
  376. The Danish Nonmelanoma Skin Cancer Dermatology Database
  377. Dynamic Optical Coherence Tomography Capillaroscopy
  378. Validation of a Screening Questionnaire for Chronic Leg Ulcers
  379. Validation of Dynamic optical coherence tomography for non-invasive, in vivo microcirculation imaging of the skin
  380. The Association between Hidradenitis Suppurativa and Crohn’s Disease: in Search of the Missing Pathogenic Link
  381. Pilonidal sinus: clinical and ultrasonographic response to topical resorcinol 15%
  382. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
  383. Renal amyloid A amyloidosis as a complication of hidradenitis suppurativa
  384. Prevalence of delayed-type and immediate-type hypersensitivity in healthcare workers with hand eczema
  385. A new algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma based onin vivoanalysis of optical properties by high-definition optical coherence tomography
  386. Optical coherence tomography of basal cell carcinoma: density and signal attenuation
  387. Adjunct use of optical coherence tomography increases the detection of recurrent basal cell carcinoma over clinical and dermoscopic examination alone
  388. In vivo assessment of optical properties of basal cell carcinoma and differentiation of BCC subtypes by high-definition optical coherence tomography
  389. Self-reported skin morbidity in Denmark: a population-based cross-sectional study
  390. What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis
  391. Usefulness of ultrasound for the diagnosis of dermatofibroma
  392. In vivo, micro-morphological vascular changes induced by topical brimonidine studied by Dynamic optical coherence tomography
  393. Mechanical stress and the development of pseudo-comedones and tunnels in Hidradenitis suppurativa/Acne inversa
  394. Acquired Localized Cutis Laxa due to Increased Elastin Turnover
  395. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa
  396. Self-reported pain management in hidradenitis suppurativa
  397. The Secret Scourge
  398. Hidradenitis Suppurativa
  399. Editorial
  400. Diagnosing Hidradenitis Suppurativa
  401. The ABC of Hidradenitis Suppurativa: A Validated Glossary on how to Name Lesions
  402. Leukocyte Profile in Peripheral Blood and Neutrophil-Lymphocyte Ratio in Hidradenitis Suppurativa: A Comparative Cross-Sectional Study of 462 Cases
  403. Pain in Hidradenitis Suppurativa: A Pilot Study
  404. A Population- and Hospital-based Cross-sectional Study of Renal Function in Hidradenitis Suppurativa
  405. Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D
  406. Dynamic Optical Coherence Tomography in Dermatology
  407. Hidradenitis suppurativa may not be associated with venous thromboembolia: Results from a large Danish cross-sectional study
  408. Optical Coherence Tomography for Skin Cancer and Actinic Keratosis
  409. New treatment strategies for hidradenitis suppurativa
  410. Body composition and basal metabolic rate in Hidradenitis Suppurativa: a Danish population-based and hospital-based cross-sectional study
  411. Comment on ‘Transient memory impairment and transient global amnesia induced by photodynamic therapy’
  412. In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomography
  413. Diagnostic delay in hidradenitis suppurativa is a global problem
  414. Hidradenitis suppurativa: A growing concern
  415. Hidradenitis suppurativa: Epidemiology and scope of the problem
  416. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes
  417. Is hidradenitis suppurativa associated with anaemia?: a population-based and hospital-based cross-sectional study from Denmark
  418. Cyclosporine treatment of severe Hidradenitis suppurativa – A case series
  419. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies
  420. Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software
  421. In vivomicro-angiography by means of speckle-variance optical coherence tomography (SV-OCT) is able to detect microscopic vascular changes in naevus to melanoma transition
  422. Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients
  423. Wound healing and all-cause mortality in 958 wound patients treated in home care
  424. Gallstones are associated with hidradenitis suppurativa
  425. The bacteriology of hidradenitis suppurativa: a systematic review
  426. A systematic review of terms used to describe hidradenitis suppurativa
  427. Methods to assess area and volume of wounds - a systematic review
  428. Through the looking‐glass, and what the dermatologist found there
  429. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study
  430. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values
  431. High-definition optical coherence tomography intrinsic skin ageing assessment in women: a pilot study
  432. Recellularizing of human acellular dermal matrices imaged by high-definition optical coherence tomography
  433. Imaging of cutaneous T-cell lymphomas by optical coherence tomography - a case series study
  434. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study
  435. The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
  436. Time Spent per delta PASI (TSdP) among psoriasis patients undergoing UVB-therapy – A pilot study
  437. Expert Advice Provided through Telemedicine Improves Healing of Chronic Wounds: Prospective Cluster Controlled Study
  438. Three-dimensional high-definition optical coherence tomography image acquisition procedure for basal cell carcinoma
  439. Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients
  440. High-definition optical coherence tomography algorithm for discrimination of basal cell carcinoma from clinical BCC imitators and differentiation between common subtypes
  441. Recurrence Rate and Patient Satisfaction of CO2 Laser Evaporation of Lesions in Patients With Hidradenitis Suppurativa
  442. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
  443. A case report of differentiating staphylococcal scalded skin syndrome and toxic epidermal necrolysis by optical coherence tomography
  444. Optical Coherence Tomography Imaging of the Skin
  445. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation
  446. Coagulation Status in Hidradenitis Suppurativa: A Danish Population- and Hospital-Based Cross-Sectional Study
  447. An Integrating Perspective
  448. How to Learn Most About Your Patients
  449. Recurring Axillary, Abdominal and Genitofemoral Nodules and Abscesses: A Quiz
  450. Actinic Keratosis
  451. Hand eczema and stratum corneum ceramides
  452. Association of Metabolic Syndrome and Hidradenitis Suppurativa
  453. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
  454. PIONEER II: Adalimumab Reduces Disease Activity in Patients with HS
  455. Hidradenitis Suppurativa
  456. Real-time three-dimensional imaging of epidermal splitting and removal by high-definition optical coherence tomography
  457. Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options
  458. Optical coherence tomography in the diagnosis of basal cell carcinoma
  459. Novel investigational therapies for atopic dermatitis
  460. Risk factors, clinical course and long‐term prognosis in hidradenitis suppurativa: a cross‐sectional study
  461. Differentiating allergic and irritant contact dermatitis by high-definition optical coherence tomography: a pilot study
  462. Optical Coherence Tomography and Cryosurgery
  463. Imaging of collagen deposition disorders using optical coherence tomography
  464. Assessing the quality of life over longer periods
  465. Pain and inflammation in hidradenitis suppurativa correspond to morphological changes identified by high-frequency ultrasound
  466. Delivery of Compression Therapy for Venous Leg Ulcers
  467. The association of metabolic syndrome and psoriasis: a population- and hospital-based cross-sectional study
  468. Cost-Effective Use of Silver Dressings for the Treatment of Hard-to-Heal Chronic Venous Leg Ulcers
  469. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?
  470. The Role of Ultrasound in Severity Assessment in Hidradenitis Suppurativa
  471. Artefactual skin lesions in children and adolescents: review of the literature and two cases of factitious purpura
  472. Pattern of contact sensitization in patients with and without atopic dermatitis in a hospital-based clinical database
  473. The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa
  474. Ultrasound as a Diagnostic Aid in Identifying Neurofibromas
  475. Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions
  476. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease
  477. Standard Grading System for Rosacea
  478. Ingenol Mebutate: From Common Weed to Cancer Cure
  479. Optical Coherence Tomography and Its Role for Delineating the Thickness of Keratinocyte Dysplasia and Neoplasia
  480. In-vivo-Darstellung einerSarcoptes-scabiei-Infestation mittels optischer Kohärenztomographie
  481. Dermatophyte Prevalence in Tools of 43 Hairdressing Salons in Copenhagen
  482. Psoriasis – The Life Course Approach
  483. Interpretation of the Skin Cancer Quality of Life Score: A Validated Quality of Life Questionnaire for Non-Melanoma Skin Cancer
  484. The Influence of Body Weight on the Prevalence and Severity of Hidradenitis Suppurativa
  485. Is Adult Atopic Eczema More Common Than We Think? – A Population-based Study in Danish Adults
  486. Significant Differences in Nurses’ Knowledge of Basic Wound Management – Implications for Treatment
  487. Self-Reported Skin Morbidities and Health-Related Quality of Life: A Population-Based Nested Case-Control Study
  488. Quality of Life in Non-Melanoma Skin Cancer—The Skin Cancer Quality of Life (SCQoL) Questionnaire
  489. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors
  490. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis
  491. Ballistometer
  492. Successful Treatment of Severe Hidradenitis Suppurativa With Anakinra
  493. Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy
  494. Photoallergic reactions to varenicline mimicking brachioradial pruritus
  495. High-definition optical coherence tomography imaging of melanocytic lesions: a pilot study
  496. Optical Coherence Tomography
  497. In vivo Imaging of Sarcoptes scabiei Infestation Using Optical Coherence Tomography
  498. Biomarkers in hidradenitis suppurativa
  499. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support
  500. Errata
  501. Disease quantification in dermatology: in vivo near-infrared spectroscopy measures correlate strongly with the clinical assessment of psoriasis severity
  502. Optical coherence tomography imaging of telangiectasias during intense pulsed light treatment: a potential tool for rapid outcome assessment
  503. Patients' perceptions of topical treatments of actinic keratosis
  504. Predicting response to anti-TNF-alpha treatment in Hidradenitis suppurativa
  505. Assessing the influence of actinic keratosis on patients’ quality of life: the AKQoL questionnaire
  506. Imaging actinic keratosis by high-definition optical coherence tomography. Histomorphologic correlation: a pilot study
  507. High-definition optical coherence tomography: adapted algorithmic method for pattern analysis of inflammatory skin diseases: a pilot study
  508. Useful Dermatologic Classifications
  509. Glossary of Dermatological Terms
  510. Cumulative Life Course Impairment in Other Chronic or Recurrent Dermatologic Diseases
  511. Sonographic Anatomy of the Skin, Appendages, and Adjacent Structures
  512. Self-Inflicted Lesions in Dermatology: Terminology and Classification – A Position Paper from the European Society for Dermatology and Psychiatry (ESDaP)
  513. Development of a Clinical Scandinavian Registry for Hidradenitis Suppurativa; HISREG
  514. Erratum
  515. Erratum
  516. Dermatologic Ultrasound with Clinical and Histologic Correlations
  517. Treatment Patterns, Treatment Satisfaction, Severity of Disease Problems, and Quality of Life in Patients with Psoriasis in Three Nordic Countries
  518. Tumour Necrosis Factor-alpha and Matrix Metalloproteinase-2 are Expressed Strongly in Hidradenitis Suppurativa
  519. Infantile Acne Treated with Oral Isotretinoin
  520. Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
  521. Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial
  522. Improving quality of life in patients with hidradenitis suppurativa: a therapeutic view
  523. Imaging of basal cell carcinoma by high-definition optical coherence tomography: histomorphological correlation. A pilot study
  524. High-definition optical coherence tomography enables visualization of individual cells in healthy skin: comparison to reflectance confocal microscopy
  525. Severity Assessment and Outcome Measures in Acne Vulgaris
  526. Diagnostic accuracy in virtual dermatopathology
  527. Imaging Cutaneous T-Cell Lymphoma with Optical Coherence Tomography
  528. Hand eczema: prevalence and risk factors of hand eczema in a population of 2274 healthcare workers
  529. Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study
  530. Peristomal Skin Complications Are Common, Expensive, and Difficult to Manage: A Population Based Cost Modeling Study
  531. Imaging the Nail Unit
  532. Exposures related to hand eczema: a study of healthcare workers
  533. Quality of life in atopic dermatitis: Changes over 6 years in patients who report persistent eczema
  534. Depression in patients with hidradenitis suppurativa
  535. Ceramide profile in hypohidrotic ectodermal dysplasia
  536. Imaging Granulomatous Lesions with Optical Coherence Tomography
  537. Hidradenitis suppurativa and immune dysregulation
  538. The efficacy of maggot debridement therapy - a review of comparative clinical trials
  539. Hidradenitis Suppurativa
  540. Cryosurgery Treatment of Actinic Keratoses Monitored by Optical Coherence Tomography: A Pilot Study
  541. Yellow plaques as cutaneous markers of internal disorders
  542. A Polycyclic Annular Erythematous Plaque on the Trunk: A Quiz
  543. Recurrent Boils of the Axilla and Groin: A Quiz
  544. The impact of ultraviolet therapy on stratum corneum ceramides and barrier function
  545. Teledermatology: The Atlantic Experience
  546. Do generalists and specialists agree on descriptive acne morphology?
  547. Hedgehog pathway does not play a role in hidradenitis suppurativa pathogenesis
  548. Long-term, continuous dosing of etanercept in patients with plaque psoriasis
  549. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
  550. Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa
  551. How histological features of basal cell carcinomas influence image quality in optical coherence tomography
  552. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa
  553. Cumulative life damage in dermatology
  554. A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp
  555. Hidradenitis suppurativa: a review of cause and treatment
  556. Ultrasound detection and identification of cosmetic fillers in the skin
  557. Assessing peristomal skin changes in ostomy patients: validation of the Ostomy Skin Tool
  558. Comparative diagnostic accuracy in virtual dermatopathology
  559. Factors related to pain during routine photodynamic therapy: a descriptive study of 301 patients
  560. The Concept of ‘Smokers’ Boils’ Is Suggestive of a New Hypothesis on the Pathogenesis of Hidradenitis Suppurativa
  561. Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients
  562. Psychosocial Impact of Hidradenitis Suppurativa: A Qualitative Study
  563. Effects of Topical Corticosteroid and Tacrolimus on Ceramides and Irritancy to Sodium Lauryl Sulphate in Healthy Skin
  564. Stereological Estimation of Epidermal Volumes and Dermo-Epidermal Surface Area in Normal Skin
  565. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation
  566. Ethnicity and stratum corneum ceramides
  567. Teledermatology with an integrated nurse - led clinic on the Faroe Islands - 7 years’ experience
  568. Treatment of hidradenitis suppurativa: Is oral isoniazid an option?
  569. Sensory Perception
  570. Dermatologic research in the Nordic countries 1989-2008 - a bibliometric study
  571. Skin barrier response to occlusion of healthy and irritated skin: Differences in trans-epidermal water loss, erythema and stratum corneum lipids
  572. The Ostomy Skin Tool: tracking peristomal skin changes
  573. Changes in skin barrier during treatment with systemic alitretinoin: focus on skin susceptibility and stratum corneum ceramides
  574. Current and future treatments of hidradenitis suppurativa
  575. Is the Dermatology Life Quality Index really time-sensitive?
  576. Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions
  577. Skin problems in stoma patients
  578. Interobserver variability of clinical scores in hidradenitis suppurativa is low
  579. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema
  580. A simple method for routine measure of photodynamic therapy-associated pain
  581. Quality of life assessment among patients with peristomal skin disease
  582. Stratum corneum integrity as a predictor for peristomal skin problems in ostomates
  583. Photodynamic Therapy
  584. Prevention and Adjuvant Therapy
  585. Accuracy in the Diagnosis of Non-Melanoma Skin Cancer
  586. Anatomical Detection of Inflammatory Changes Associated with Plantar Warts by Ultrasound
  587. Comment on: Tattooing of skin results in transportation and light-induced decomposition of tattoo pigments
  588. Anaerobic digestion of tannery waste: Semi-continuous and anaerobic sequencing batch reactor processes
  589. Hidradenitis Suppurativa Complicating Naevus Comedonicus: The Possible Influence of Mechanical Stress on the Development of Hidradenitis Suppurativa
  590. Ceramides and Barrier Function in Healthy Skin
  591. High Body Mass Index in Adolescent Girls Precedes Psoriasis Hospitalization
  592. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa
  593. To Cut or Not, That Is the Question
  594. Validation of Cyanoacrylate Method for Collection of Stratum Corneum in Human Skin for Lipid Analysis
  595. Application of stereology to dermatological research
  596. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus
  597. Optical coherence tomography imaging of psoriasis vulgaris: correlation with histology and disease severity
  598. Involuntary autonomy: Patients' perceptions of physicians, conventional medicines and risks in the management of atopic dermatitis
  599. Involuntary autonomy: Patients' perceptions of physicians, conventional medicines and risks in the management of atopic dermatitis☆
  600. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
  601. Optical Coherence Tomography for Imaging of Skin and Skin Diseases
  602. Improved quality of optical coherence tomography imaging of basal cell carcinomas using speckle reduction
  603. Which histological characteristics of basal cell carcinomas influence the quality of optical coherence tomography imaging?
  604. OCT imaging of skin cancer and other dermatological diseases
  605. Assessment of Optical Coherence Tomography Imaging in the Diagnosis of Non-Melanoma Skin Cancer and Benign Lesions Versus Normal Skin
  606. Sonography of Plantar Warts
  607. In vivothickness measurement of basal cell carcinoma and actinic keratosis with optical coherence tomography and 20-MHz ultrasound
  608. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases
  609. Alitretinoin – its use in intractable hand eczema and other potential indications
  610. Lymph Nodes in Hidradenitis Suppurativa
  611. Non-Surgical Treatment of Keratinocyte Skin Cancer
  612. Role of High-Variable Frequency Ultrasound in Preoperative Diagnosis of Glomus Tumors
  613. The Effect of Combined Treatment with Oral Clindamycin and Oral Rifampicin in Patients with Hidradenitis Suppurativa
  614. Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors
  615. Widespread Mycobacterium marinum Infection
  616. Skin Problems in Ostomy Patients: A Case-control Study of Risk Factors
  617. Stratum Corneum Damage and ex vivo Porcine Skin Water Absorption – A Pilot Study
  618. Photodynamic Therapy of Necrobiosis Lipoidica – A Multicenter Study of 18 Patients
  619. Optical coherence tomography imaging of bullous diseases
  620. Teledermatology on the Faroe Islands
  621. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial
  622. Peristomal skin problems account for more than one in three visits to ostomy nurses
  623. Machine-learning classification of non-melanoma skin cancers from image features obtained by optical coherence tomography
  624. Photodynamic Therapy With Methyl Aminolevulinate for Prevention of New Skin Lesions in Transplant Recipients: A Randomized Study
  625. FS03.4
Irritant dermatitis following tape stripping
  626. The revolutionary consequences of skin disease
  627. Viewpoint 1
  628. Lipids and skin barrier function – a clinical perspective
  629. What causes hidradenitis suppurativa?
  630. Sonography of the Ear Pinna
  631. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
  632. Hidradénite suppurée
  633. Morphology and Epidermal Thickness of Normal Skin Imaged by Optical Coherence Tomography
  634. Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology
  635. Real-Time Compound Imaging Ultrasound of Hidradenitis Suppurativa
  636. Real-Time Compound Imaging Ultrasound of Hidradenitis Suppurativa
  637. Imaging of intradermal tattoos by optical coherence tomography
  638. Nail thickness measurements using optical coherence tomography and 20-MHz ultrasonography
  639. Diagnosis of Nonmelanoma Skin Cancer/Keratinocyte Carcinoma
  640. Diagnosis of Nonmelanoma Skin Cancer/Keratinocyte Carcinoma: A Review of Diagnostic Accuracy of Nonmelanoma Skin Cancer Diagnostic Tests and Technologies
  641. Assessment of atopic eczema: clinical scoring and noninvasive measurements
  642. Diagnostic potential of optical coherence tomography in non-melanoma skin cancer: a clinical study
  643. Imaging of cutaneous larva migrans by optical coherence tomography
  644. Photodynamic therapy in a series of rosacea patients
  645. THE CAUSES OF PERISTOMAL SKIN DISORDERS
  646. Pain and Photodynamic Therapy
  647. Diagnostic Potential of Optical Coherence Tomography in Non-Melanoma Skin Cancer - A Clinical Study
  648. Outcomes in randomized controlled trials in psoriasis: What has changed over the last 20 years?
  649. Management of actinic keratosis patients: A qualitative study
  650. Successful Treatment of Necrobiosis Lipoidica Diabeticorum With Photodynamic Therapy
  651. Instrumental assessment of atopic eczema: Validation of transepidermal water loss, stratum corneum hydration, erythema, scaling, and edema
  652. Study of peristomal skin disorders in patients with permanent stomas
  653. A bibliometric study of dermatology in central Europe 1991–2002
  654. Ultrasound Imaging of Nails
  655. Life quality assessment among patients with atopic eczema
  656. Parent gender and assessment of infant life quality
  657. The handicap caused by atopic dermatitis - sick leave and job avoidance
  658. Handbook of Non-Invasive Methods and the Skin, Second Edition
  659. Ultrasound Imaging of Subcutaneous Tissue and Adjacent Structures
  660. Hidradenitis Suppurativa
  661. The bacterial flora of the skin surface following routine MAL‐PDT
  662. Mechanical Properties and Barrier Function of Healthy Human Skin
  663. Low‐dose allopurinol in the treatment of cutaneous sarcoidosis: Response in four of seven patients
  664. The silver-releasing foam dressing, Contreet Foam, promotes faster healing of critically colonised venous leg ulcers: a randomised, controlled trial
  665. Photodynamic Therapy in the Treatment of Rosacea
  666. Methotrexate Use and Monitoring in Switzerland and Denmark
  667. Does visible atopic dermatitis affect quality of life more in women than in men?
  668. Time Spent on Treatment of Atopic Dermatitis: A New Method of Measuring Pediatric Morbidity?
  669. Acne: Treatment of scars
  670. Medical treatment of hidradenitis suppurativa
  671. Topical Therapy for Peristomal Pyoderma Gangrenosum
  672. Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa
  673. Real-time spatial compound ultrasound imaging of skin
  674. ULTRASONIDO DE ALTA RESOLUCION (15 MHz) EN EL ESTUDIO DE LA UÑA PSORIATICA
  675. HuMax-CD4
  676. Acne: comparing hormonal approaches to antibiotics and isotretinoin
  677. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa
  678. Mechanical properties of the skin: A comparison between two suction cup methods
  679. Nonmelanoma skin cancer in organ transplant patients
  680. Acne: comparing hormonal approaches to antibiotics and isotretinoin
  681. Combined imiquimod and acitretin for non-surgical treatment of basal cell carcinoma
  682. Hidradenitis Suppurativa
  683. Hydration and Plasticity Following Long-term Use of a Moisturizer: A Single-blind Study
  684. Methotrexate is of limited value in the treatment of hidradenitis suppurativa
  685. The Mechanical Properties of Skin in Osteogenesis Imperfecta
  686. Have Oral Contraceptives Reduced the Prevalence of Acne? A Population-Based Study of Acne vulgaris, Tobacco Smoking and Oral Contraceptives
  687. Braces for Postoperative Bandage After Otoplasty
  688. The therapeutic potential of calcipotriol in diseases other than psoriasis
  689. Isotretinoin in Denmark - 20 years on
  690. Skin Irritation and Exposure to Diisocyanates in Orthopedic Nurses Working With Soft Casts
  691. Skin Irritation and Exposure to Diisocyanates in Orthopedic Nurses Working With Soft Casts
  692. Skin irritation and exposure to diisocyanates in orthopedic nurses working with soft casts
  693. Impact factors of dermatological journals for 1991 – 2000
  694. Impact factor to assess academic output
  695. Anxiety level and severity of skin condition predicts outcome of psychotherapy in atopic dermatitis patients
  696. Crohn's disease presenting as a breast abscess: A case report
  697. Measuring skin mechanics. The soft touch in a hard environment?
  698. Measurement of the mechanical properties of skin with ballistometer and suction cup
  699. Morbidity in patients with hidradenitis suppurativa
  700. Vasculitis Occurring during Leflunomide Therapy
  701. Anxiety, Aggression, and Body Ideal in Adult Atopic Dermatitis Patients
  702. Moisturisers for Psoriatic Skin –Do Gross Morphological Differences Matter?
  703. Treatment of perforating collagenosis of diabetes and renal failure with allopurinol
  704. What's new in hidradenitis suppurativa?
  705. Ethical considerations
  706. The Inherent Capacitance of Moisturising Creams: A Source of False Positive Results?
  707. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa
  708. Hydration of human nails investigated by NIR-FT-Raman spectroscopy
  709. Correlation Between the Greasiness and the Plasticizing Effect of Moisturizers
  710. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis
  711. Gerda Frentz (1942?1998)
  712. Plasticising effect of water and glycerin on human skin in vivo
  713. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa
  714. Stellungnahme zur Arbeit von D. Abeck, H.C. Korting, M. Mempel: „Pyodermien”
  715. Evidence-based dermatologic out-patient treatment
  716. Quantitative evaluation of chronological ageing and photoageing in vivo: studies on skin echogenicity and thickness
  717. Relationship between keratinocyte adhesion and death: anoikis in acantholytic diseases
  718. The plastic sing effect of moisturizers on human skin in vivo: a measure of moisturizing potency?
  719. Quality assurance in dermatology - the development of a framework
  720. Ultrasound examination of hair follicles in hidradenitis suppurativa
  721. Pincer Nails and Alopecia as Markers of Gastrointestinal Malignancy
  722. Assessment of morbidity from skin diseases
  723. The changing referral pattern in Danish dermatology - Rigshospitalet, Copenhagen, 1986-1995
  724. The homogeneity of hidradenitis suppurativa lesions
  725. Sebum Excretion in Hidradenitis suppurativa
  726. Measurement of skin mechanics.
  727. Hidradenitis suppurativa - characteristics and consequences
  728. The prevalence of hidradenitis suppurativa and its potential precursor lesions
  729. Treatment of hyper-IgE dermatitis with interferon-γ
  730. Reply
  731. Treatment of hyper-IgE dermatitis with interferon-γ
  732. Nail abnormalities in nondermatologic patients
  733. Histology of hidradenitis suppurativa
  734. Quality assurance in clinical dermatology - a need for tools
  735. Patient-physician consensus on quality of life in dermatology
  736. Topical Treatment of Skin Ulcers in Prolidase Deficiency
  737. Topical Treatment of Skin Ulcers in Prolidase Deficiency
  738. Decreased Bone Mineral Density in Patients with Pustulosis palmaris et plantaris
  739. The Bacteriology of Hidradenitis suppurativa
  740. Coping and psoriasis ? a framework for targeted intervention
  741. A retrospective comparison of inpatient tar therapy and outpatient UVB irradiation therapy in psoriasis
  742. Occupational allergic contact dermatitis from vitamin A acetate
  743. Microbiology of hidradenitis suppurativa
  744. Intra-individual variation of hidradenitis suppurativa
  745. Contact sensitization to dipropylene glycol in an eczema population
  746. Nail abnormalities in nondermatologic patients: Prevalence and possible role as diagnostic aids
  747. The influence of sex hormones on UVB induced erythema in man
  748. Erythema-index of clinical patch test reactions
  749. Dipropylene Glycol Allergy: A Hidden Cause of Perfume Contact Dermatitis
  750. Dipropylene Glycol Allergy: A Hidden Cause of Perfume Contact Dermatitis
  751. Cancer in patients treated with coal tar: a long-term follow up study
  752. Effect of cyclosporine on genital psoriasis and lichen planus
  753. Bone mineral density is unaffected by palmoplantar pustulosis
  754. Primary prevention of malignant melanoma: To know may not be enough
  755. Concomitant Psoriasis and Allergic Contact Dermatitis: Coexistent Interrelated Clinical Entities
  756. Concomitant Psoriasis and Allergic Contact Dermatitis: Coexistent Interrelated Clinical Entities
  757. Contact dermatitis from Brazilian box tree wood (Aspidospermasp.)
  758. Circulating androgens in male patients suffering from systemic scleroderma
  759. Side effects of cryotherapy
  760. Clofazimine for Residual Nodulocystic Acne Lesions
  761. Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis
  762. Reply
  763. The Effect of Superficial Hydration on the Mechanical Properties of Human Skin in Vivo
  764. Unusual immediate adverse effects of photochemotherapy
  765. Transonychial water loss: relation to sex, age and nail-plate thickness
  766. Short-term effects of topical 17β-oestradiol on human post-menopausal skin
  767. Ultrasound Structure of the Human Nail Plate
  768. Ultrasound structure of the human nail plate
  769. Bone lesions of acne fulminans
  770. The symptomatology of hidradenitis suppurativa in women
  771. Effect of localized surgical excisions in hidradenitis suppurativa
  772. Linear Atrophy Following Intralesional Steroid Injections
  773. HIDRADENITIS SUPPURATIVA
  774. The distribution of p29 protein in normal human skin
  775. Photographic surgery: Standards in clinical photography
  776. Hypertrichosis Lanuginosa Acquisita
  777. Hypertrichosis lanuginosa acquisita. Report of a case and review of the literature
  778. Suggestions for standardized clinical photography in plastic surgery
  779. Clinique
  780. Nosologie et classification
  781. Traitement
  782. Imaging
  783. Imagerie
  784. Traitements physiques expérimentaux
  785. Traitement immunodépresseur et hidradénite suppurée
  786. Traitement topique
  787. Affections associées : causalité ou complications?
  788. Topical Treatment
  789. Treatment
  790. Clinical Presentation
  791. Experimental Physical Therapies
  792. Associated Diseases: Causality or Complications?
  793. Immunosuppressive Therapy in Hidradenitis Suppurativa
  794. Nosology and Classification
  795. Optical Coherence Tomography: Technique and Applications